|
US4327725A
(en)
|
1980-11-25 |
1982-05-04 |
Alza Corporation |
Osmotic device with hydrogel driving member
|
|
DE3303707A1
(de)
|
1983-02-04 |
1984-08-09 |
Dynamit Nobel Ag, 5210 Troisdorf |
Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
|
|
US4624848A
(en)
|
1984-05-10 |
1986-11-25 |
Ciba-Geigy Corporation |
Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
|
|
US4968509A
(en)
|
1987-07-27 |
1990-11-06 |
Mcneilab, Inc. |
Oral sustained release acetaminophen formulation and process
|
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
|
JPH01167840A
(ja)
|
1987-12-24 |
1989-07-03 |
Konica Corp |
新規な写真用シアンカプラー
|
|
IL92966A
(en)
|
1989-01-12 |
1995-07-31 |
Pfizer |
Dispensing devices powered by hydrogel
|
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
|
DE69222847T3
(de)
|
1991-04-16 |
2005-09-15 |
Nippon Shinyaku Co., Ltd. |
Verfahren zur herstellung einer festen dispersion
|
|
HU227530B1
(en)
|
1991-11-22 |
2011-07-28 |
Warner Chilcott Company |
Delayed-release compositions containing risedronate and process for their production
|
|
US5461140A
(en)
|
1992-04-30 |
1995-10-24 |
Pharmaceutical Delivery Systems |
Bioerodible polymers for solid controlled release pharmaceutical compositions
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
WO1994008568A1
(fr)
|
1992-10-16 |
1994-04-28 |
Nippon Shinyaku Co., Ltd. |
Procede pour fabriquer des matrices de cire
|
|
GB9226855D0
(en)
|
1992-12-23 |
1993-02-17 |
Erba Carlo Spa |
Vinylene-azaindole derivatives and process for their preparation
|
|
US5686105A
(en)
|
1993-10-19 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
|
US6326469B1
(en)
|
1994-04-22 |
2001-12-04 |
Sugen, Inc. |
Megakaryocytic protein tyrosine kinases
|
|
JPH11505258A
(ja)
|
1995-05-17 |
1999-05-18 |
セダーシナイ メディカル センター |
小腸における消化および吸収を改善させる脂肪酸を含む組成物
|
|
US5593997A
(en)
|
1995-05-23 |
1997-01-14 |
Pfizer Inc. |
4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
|
|
US5994348A
(en)
|
1995-06-07 |
1999-11-30 |
Sanofi |
Pharmaceutical compositions containing irbesartan
|
|
CH690773A5
(de)
|
1996-02-01 |
2001-01-15 |
Novartis Ag |
Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
|
|
AU3176297A
(en)
|
1996-06-25 |
1998-01-14 |
Novartis Ag |
Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
|
|
HUP0001507A3
(en)
|
1997-03-19 |
2002-01-28 |
Abbott Gmbh & Co Kg |
Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
|
|
ATE364374T1
(de)
|
1997-08-11 |
2007-07-15 |
Pfizer Prod Inc |
Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
|
|
WO1999033467A1
(en)
|
1997-12-31 |
1999-07-08 |
Choongwae Pharma Corporation |
Method and composition of an oral preparation of itraconazole
|
|
US6303652B1
(en)
|
1998-08-21 |
2001-10-16 |
Hughes Institute |
BTK inhibitors and methods for their identification and use
|
|
HUP0102661A2
(hu)
|
1998-04-17 |
2001-11-28 |
Parker Hughes Institute |
BTK-inhibitorok és a BTK-inhibitorok azonosítására szolgáló eljárások, valamint alkalmazásuk
|
|
US7122207B2
(en)
|
1998-05-22 |
2006-10-17 |
Bristol-Myers Squibb Company |
High drug load acid labile pharmaceutical composition
|
|
US20050287596A9
(en)
|
1998-06-26 |
2005-12-29 |
Braisted Andrew C |
Novel ligands and libraries of ligands
|
|
US6998233B2
(en)
|
1998-06-26 |
2006-02-14 |
Sunesis Pharmaceuticals, Inc. |
Methods for ligand discovery
|
|
US6335155B1
(en)
|
1998-06-26 |
2002-01-01 |
Sunesis Pharmaceuticals, Inc. |
Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
|
|
UA74141C2
(uk)
|
1998-12-09 |
2005-11-15 |
Дж.Д. Сірл Енд Ко. |
Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
|
|
DE60039379D1
(de)
|
1999-02-10 |
2008-08-21 |
Pfizer Prod Inc |
Pharmazeutische feste Dispersionen
|
|
US6306897B1
(en)
|
1999-03-19 |
2001-10-23 |
Parker Hughes Institute |
Calanolides for inhibiting BTK
|
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
|
DK1212327T3
(da)
|
1999-09-17 |
2003-12-15 |
Abbott Gmbh & Co Kg |
Pyrazolopyrimidiner som terapeutiske midler
|
|
US6506769B2
(en)
|
1999-10-06 |
2003-01-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
|
DE60014130T2
(de)
|
1999-10-06 |
2006-03-09 |
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield |
Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
|
|
CA2390857A1
(en)
|
1999-11-30 |
2001-06-14 |
Fatih M. Uckun |
Inhibitors of collagen-induced platelet aggregation
|
|
CA2394650A1
(en)
|
1999-12-17 |
2001-06-21 |
Chi B. Vu |
Novel heterocycles
|
|
GB0005345D0
(en)
|
2000-03-06 |
2000-04-26 |
Mathilda & Terence Kennedy Ins |
Methods of treating sepsis septic shock and inflammation
|
|
GB0108903D0
(en)
|
2000-10-05 |
2001-05-30 |
Aventis Pharm Prod Inc |
Novel crystalline forms of a factor Xa inhibitor
|
|
JP2004533209A
(ja)
|
2000-10-23 |
2004-11-04 |
ブリストル−マイヤーズ スクイブ カンパニー |
ブルトンチロシンキナーゼおよびブルトンチロシンキナーゼ媒体のモデュレーターおよびその同定方法および骨粗鬆症および関連疾患状態の治療および予防におけるその使用
|
|
AU2002232492A1
(en)
|
2000-12-06 |
2002-06-18 |
Pharmacia Corporation |
Rapidly dispersing pharmaceutical composition comprising effervescent agents
|
|
US6465014B1
(en)
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
|
US8306897B2
(en)
|
2001-05-04 |
2012-11-06 |
Stockshield, Inc. |
Method and system for insuring against investment loss
|
|
EP1463742A4
(en)
|
2001-06-21 |
2006-05-10 |
Ariad Pharma Inc |
NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
|
|
US20030119060A1
(en)
|
2001-08-10 |
2003-06-26 |
Desrosiers Peter J. |
Apparatuses and methods for creating and testing pre-formulations and systems for same
|
|
CA2450777C
(en)
|
2001-08-10 |
2013-04-09 |
Novartis Ag |
Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
|
|
WO2003016338A1
(en)
|
2001-08-15 |
2003-02-27 |
Parker Hughes Institute |
Crystal structure of the btk kinase domain
|
|
JP4391237B2
(ja)
|
2001-11-21 |
2009-12-24 |
サネシス ファーマシューティカルズ， インコーポレイテッド |
リガンド発見のための方法
|
|
US20050084905A1
(en)
|
2002-03-21 |
2005-04-21 |
Prescott John C. |
Identification of kinase inhibitors
|
|
GB2388594A
(en)
|
2002-05-16 |
2003-11-19 |
Bayer Ag |
Imidazo-triazine PDE 4 inhibitors
|
|
AU2003257094A1
(en)
|
2002-08-08 |
2004-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Substituted benzimidazole compounds
|
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US7687506B2
(en)
|
2003-04-11 |
2010-03-30 |
The Regents Of The University Of California |
Selective serine/threonine kinase inhibitors
|
|
US20050008640A1
(en)
|
2003-04-23 |
2005-01-13 |
Wendy Waegell |
Method of treating transplant rejection
|
|
EP1473039A1
(en)
|
2003-05-02 |
2004-11-03 |
Centre National De La Recherche Scientifique (Cnrs) |
Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
|
|
WO2005014599A1
(en)
|
2003-06-04 |
2005-02-17 |
Cellular Genomics, Inc. |
Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
|
|
US7393848B2
(en)
|
2003-06-30 |
2008-07-01 |
Cgi Pharmaceuticals, Inc. |
Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
|
|
CA2537254A1
(en)
|
2003-09-03 |
2005-03-17 |
Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services |
Methods for identifying, diagnosing, and predicting survival of lymphomas
|
|
US8131475B2
(en)
|
2003-09-03 |
2012-03-06 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Methods for identifying, diagnosing, and predicting survival of lymphomas
|
|
CN1897950A
(zh)
|
2003-10-14 |
2007-01-17 |
惠氏公司 |
稠合芳基和杂芳基衍生物及其使用方法
|
|
ES2372694T3
(es)
|
2003-10-15 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
|
|
US20070196395A1
(en)
|
2003-12-12 |
2007-08-23 |
Mackerell Alexander |
Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
|
|
US20070281907A1
(en)
|
2003-12-22 |
2007-12-06 |
Watkins William J |
Kinase Inhibitor Phosphonate Conjugates
|
|
US20050153990A1
(en)
|
2003-12-22 |
2005-07-14 |
Watkins William J. |
Phosphonate substituted kinase inhibitors
|
|
PL1701698T3
(pl)
|
2004-01-08 |
2008-03-31 |
Wyeth Corp |
Prasowana bezpośrednio kompozycja farmaceutyczna do podawania doustnego CCI-779
|
|
AU2005228845A1
(en)
|
2004-01-26 |
2005-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
JP2007520559A
(ja)
|
2004-02-03 |
2007-07-26 |
アボット・ラボラトリーズ |
治療薬としてのアミノベンゾオキサゾール類
|
|
ITMI20041314A1
(it)
|
2004-06-30 |
2004-09-30 |
Nuvera Fuel Cells Europ Srl |
Dispositivo di raffreddamento per celle a combustibili a membrana
|
|
TW200613306A
(en)
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
|
WO2006036941A2
(en)
|
2004-09-27 |
2006-04-06 |
Kosan Biosciences Incorporated |
Specific kinase inhibitors
|
|
EA200700757A1
(ru)
|
2004-09-28 |
2007-10-26 |
Янссен Фармацевтика Н.В. |
Замещённые дипиперидиновые антагонисты ccr2
|
|
RU2007121508A
(ru)
|
2004-11-10 |
2008-12-20 |
Сги Фармасьютиклз |
Определенные имидазо[1, 2-а]пиразин-8-иламины, методы их получения и методы их применения
|
|
GB0425035D0
(en)
|
2004-11-12 |
2004-12-15 |
Novartis Ag |
Organic compounds
|
|
DE602006017188D1
(de)
|
2005-03-07 |
2010-11-11 |
Bayer Schering Pharma Ag |
Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
|
|
AU2006223409B2
(en)
|
2005-03-10 |
2011-07-21 |
Gilead Connecticut, Inc. |
Certain substituted amides, method of making, and method of use thereof
|
|
BRPI0610278A2
(pt)
|
2005-05-13 |
2010-06-08 |
Irm Llc |
compostos e composições como inibidores de proteìna cinase
|
|
JP2008542289A
(ja)
|
2005-05-23 |
2008-11-27 |
ノバルティス アクチエンゲゼルシャフト |
４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１イル）−１ｈ−ベンズイミダゾール−２−イル］−１ｈ−キノリン−２−オン乳酸塩の結晶およびその他の形態
|
|
WO2007002325A1
(en)
|
2005-06-22 |
2007-01-04 |
Plexxikon, Inc. |
Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
|
|
US20070065449A1
(en)
|
2005-09-16 |
2007-03-22 |
Claire Verschraegen |
Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
|
|
CA2629314A1
(en)
|
2005-11-12 |
2007-05-24 |
Boehringer Ingelheim International Gmbh |
Tec kinase inhibitors
|
|
KR20080098490A
(ko)
|
2006-01-13 |
2008-11-10 |
파마시클릭스, 인코포레이티드 |
티로신 키나제 억제제 및 이의 용도
|
|
EP1984030B1
(en)
|
2006-01-30 |
2013-05-08 |
The Scripps Research Institute |
Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
|
|
CA2645566A1
(en)
|
2006-03-20 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
|
DK2004654T3
(da)
|
2006-04-04 |
2013-07-22 |
Univ California |
Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
|
|
EP2865381A1
(en)
|
2006-05-18 |
2015-04-29 |
Pharmacyclics, Inc. |
ITK inhibitors for treating blood cell malignancies
|
|
DE102006026583A1
(de)
|
2006-06-07 |
2007-12-13 |
Bayer Healthcare Aktiengesellschaft |
Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
|
|
CA2663116C
(en)
|
2006-09-22 |
2014-06-10 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
CA2668286C
(en)
|
2006-11-03 |
2014-09-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
|
FI20080352A0
(fi)
|
2008-05-09 |
2008-05-09 |
Atacama Labs Oy |
Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi
|
|
US20100143420A1
(en)
|
2007-01-22 |
2010-06-10 |
Dinesh Shenoy |
Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability
|
|
NL2000640C2
(nl)
|
2007-03-05 |
2008-09-08 |
Stichting Wetsus Ct Of Excelle |
Werkwijze en systeem voor het zuiveren van een vloeistof.
|
|
US8809273B2
(en)
|
2007-03-28 |
2014-08-19 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
|
US20120065201A1
(en)
|
2007-03-28 |
2012-03-15 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
EP2560007A1
(en)
|
2007-03-28 |
2013-02-20 |
Pharmacyclics, Inc. |
Identification of bruton's tyrosine kinase inhibitors
|
|
US20090010911A1
(en)
|
2007-04-06 |
2009-01-08 |
Iowa State University Research Foundation, Inc. |
Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
|
|
PE20090422A1
(es)
|
2007-04-27 |
2009-04-18 |
Purdue Pharma Lp |
Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1
|
|
CN101808516B
(zh)
|
2007-07-30 |
2013-08-28 |
阿迪生物科学公司 |
作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
|
|
AU2008314632B2
(en)
|
2007-10-19 |
2015-05-28 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
CA2701275C
(en)
|
2007-10-23 |
2016-06-21 |
F. Hoffmann-La Roche Ag |
Kinase inhibitors
|
|
US8426441B2
(en)
|
2007-12-14 |
2013-04-23 |
Roche Palo Alto Llc |
Inhibitors of bruton's tyrosine kinase
|
|
US20150152115A1
(en)
|
2007-12-27 |
2015-06-04 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
EP3090743A1
(en)
|
2008-01-09 |
2016-11-09 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions for treating headache and eliminating nausea
|
|
AU2009235426A1
(en)
|
2008-04-09 |
2009-10-15 |
Lek Pharmaceuticals D.D. |
Granulation of active pharmaceutical ingredients
|
|
WO2009129246A2
(en)
|
2008-04-14 |
2009-10-22 |
Ardea Biosciences, Inc. |
Compositions and methods for preparing and using same
|
|
EP2123626A1
(en)
|
2008-05-21 |
2009-11-25 |
Laboratorios del Dr. Esteve S.A. |
Co-crystals of duloxetine and co-crystal formers for the treatment of pain
|
|
CA3031835C
(en)
|
2008-06-27 |
2021-09-07 |
Celgene Car Llc |
Heteroaryl compounds and uses thereof
|
|
CN102159214A
(zh)
|
2008-07-16 |
2011-08-17 |
药品循环公司 |
用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
|
|
MX2011001005A
(es)
|
2008-07-29 |
2011-09-01 |
Frontier Scient Inc |
Uso de derivados de tetraquis (n-alquilpiridinio)-porfirina para eliminacion de microbios o prevencion del crecimiento.
|
|
MX2011003731A
(es)
*
|
2008-10-09 |
2011-08-03 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Uso de solventes organicos en la granulacion humeda de moxifloxacino.
|
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
|
WO2010068806A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
|
|
JP5656976B2
(ja)
|
2009-04-29 |
2015-01-21 |
ローカス ファーマシューティカルズ インコーポレイテッド |
ピロロトリアジン化合物
|
|
NZ598705A
(en)
|
2009-09-16 |
2014-06-27 |
Celgene Avilomics Res Inc |
Protein kinase conjugates and inhibitors
|
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
|
PL2578585T3
(pl)
|
2010-05-31 |
2017-01-31 |
Ono Pharmaceutical Co., Ltd. |
Pochodna purynonu jako inhibitor kinazy btk
|
|
MX342405B
(es)
|
2010-06-03 |
2016-09-28 |
Pharmacyclics Inc |
El uso de inhibidores de la tirosina quinasa de bruton (btk).
|
|
US20120071497A1
(en)
*
|
2010-06-03 |
2012-03-22 |
Pharmacyclics, Inc. |
Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
|
|
PT2975042T
(pt)
|
2010-06-23 |
2019-01-11 |
Hanmi Science Co Ltd |
Novos derivados de pirimidina fundidos para inibição de atividade de tirosina-quinase
|
|
CN105566229A
(zh)
|
2010-08-10 |
2016-05-11 |
西建阿维拉米斯研究公司 |
Btk抑制剂的苯磺酸盐及其用途和制备方法
|
|
EP2603511B1
(en)
|
2010-08-12 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
|
US8541391B2
(en)
|
2010-10-28 |
2013-09-24 |
Viropharma Incorporated |
Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
|
|
US8501484B2
(en)
|
2011-03-14 |
2013-08-06 |
Los Alamos National Security, Llc |
Preparation of cerium halide solvate complexes
|
|
MX2011004759A
(es)
|
2011-05-04 |
2012-11-21 |
Senosiain S A De C V Lab |
Nuevas formas solidas de antibioticos.
|
|
AU2012255860C1
(en)
|
2011-05-17 |
2015-12-10 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
EP2734207A4
(en)
*
|
2011-07-18 |
2015-06-17 |
Tokai Pharmaceuticals Inc |
NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROSTATE CANCER
|
|
IL299533B2
(en)
|
2011-09-02 |
2025-01-01 |
Incyte Holdings Corp |
Heterocycloamines as PI3K inhibitors
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
PL3181122T3
(pl)
|
2012-01-13 |
2023-07-31 |
Xspray Pharma Ab (Publ) |
Kompozycja farmaceutyczna dazatynibu
|
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
|
JP5514256B2
(ja)
|
2012-05-18 |
2014-06-04 |
株式会社東芝 |
磁気記憶素子及びその製造方法
|
|
TWI662964B
(zh)
|
2012-06-04 |
2019-06-21 |
美商製藥有限責任公司 |
布魯頓氏酪胺酸激酶抑制劑之結晶形式
|
|
DK2861599T3
(da)
|
2012-06-18 |
2020-03-02 |
Principia Biopharma Inc |
Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme
|
|
WO2014004707A1
(en)
|
2012-06-29 |
2014-01-03 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
|
CN104704129A
(zh)
|
2012-07-24 |
2015-06-10 |
药品循环公司 |
与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
|
|
CN103121999A
(zh)
|
2012-08-29 |
2013-05-29 |
苏州迪飞医药科技有限公司 |
一种酪氨酸激酶抑制剂pci-32765的合成方法
|
|
CN104854107A
(zh)
|
2012-11-15 |
2015-08-19 |
药品循环公司 |
作为激酶抑制剂的吡咯并嘧啶化合物
|
|
HK1215374A1
(zh)
|
2013-04-08 |
2016-08-26 |
Pharmacyclics Llc |
依鲁替尼联合疗法
|
|
WO2014179528A2
(en)
|
2013-05-01 |
2014-11-06 |
Brown Dennis M |
Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
|
|
SG11201509842SA
(en)
|
2013-05-30 |
2015-12-30 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
|
TWI649081B
(zh)
|
2013-08-02 |
2019-02-01 |
製藥公司 |
治療固態腫瘤之方法
|
|
US10253244B2
(en)
|
2013-09-04 |
2019-04-09 |
Halliburton Energy Services, Inc. |
Scale-inhibiting cocrystals for treatment of a subterranean formation
|
|
AU2014318614B2
(en)
|
2013-09-12 |
2021-01-07 |
Dana-Farber Cancer Institute Inc. |
Methods for evaluating and treating Waldenstrom's macroglobulinemia
|
|
CN104447701B
(zh)
|
2013-09-17 |
2019-03-22 |
广东东阳光药业有限公司 |
吡唑类衍生物及其用途
|
|
TWI660739B
(zh)
|
2013-10-25 |
2019-06-01 |
製藥公司 |
使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
|
|
WO2015071432A1
(en)
|
2013-11-14 |
2015-05-21 |
Sandoz Ag |
Pharmaceutical compositions of ibrutinib
|
|
CN103694241A
(zh)
|
2013-11-27 |
2014-04-02 |
苏州晶云药物科技有限公司 |
Pci-32765的新晶型a及其制备方法
|
|
US20160310417A1
(en)
|
2013-12-20 |
2016-10-27 |
Emory University |
Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents
|
|
CN105949197A
(zh)
|
2014-01-29 |
2016-09-21 |
苏州晶云药物科技有限公司 |
依鲁替尼的新晶型及其制备方法
|
|
EP3102190A4
(en)
|
2014-02-07 |
2017-09-06 |
Auspex Pharmaceuticals, Inc. |
Novel pharmaceutical formulations
|
|
US20150231077A1
(en)
|
2014-02-17 |
2015-08-20 |
The Cleveland Clinic Foundation |
Amine passivated nanoparticles for cancer treatment and imaging
|
|
WO2015127261A1
(en)
|
2014-02-21 |
2015-08-27 |
Pharmacyclics, Inc. |
Biomarkers for predicting response of dlbcl to treatment with ibrutinib
|
|
US20150267752A1
(en)
|
2014-03-19 |
2015-09-24 |
Roller Bearing Company Of America, Inc. |
Bearing outer race having a radially inwardly biased seal
|
|
JP2017509336A
(ja)
|
2014-03-20 |
2017-04-06 |
ファーマサイクリックス エルエルシー |
ホスホリパーゼｃガンマ２及び耐性に関連した変異
|
|
WO2015145415A2
(en)
|
2014-03-27 |
2015-10-01 |
Perrigo Api Ltd. |
Ibrutinib solid forms and production process therefor
|
|
CN105085529A
(zh)
|
2014-05-15 |
2015-11-25 |
广东东阳光药业有限公司 |
依鲁替尼新晶型及其制备方法
|
|
US9127069B1
(en)
*
|
2014-06-11 |
2015-09-08 |
Antecip Bioventures LLC |
Compositions comprising rank/rankl antagonists and related compounds for treating pain
|
|
US20150110871A1
(en)
|
2014-06-02 |
2015-04-23 |
David Wong |
Gastric retentive tablet compositions
|
|
US20160008777A1
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting Inc. |
Pharmaceutical compounding kit
|
|
PT107846B
(pt)
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
|
|
WO2016020697A1
(en)
|
2014-08-06 |
2016-02-11 |
Cipla Limited |
Pharmaceutical compositions of polymeric nanoparticles
|
|
SG11201700849XA
(en)
|
2014-08-07 |
2017-03-30 |
Pharmacyclics Llc |
Novel formulations of a bruton's tyrosine kinase inhibitor
|
|
WO2016025720A1
(en)
|
2014-08-14 |
2016-02-18 |
Assia Chemical Industries Ltd. |
Solid state forms of ibrutinib
|
|
EP3201197B1
(en)
|
2014-10-01 |
2019-03-27 |
ratiopharm GmbH |
Acid addition salt of ibrutinib
|
|
CN104523695A
(zh)
*
|
2014-11-12 |
2015-04-22 |
广东东阳光药业有限公司 |
一种治疗过度增生性疾病的药物组合物
|
|
CN105640961A
(zh)
|
2014-11-18 |
2016-06-08 |
山东瑞禾医药科技有限公司 |
一种含依鲁替尼的药物组合物
|
|
WO2016079216A1
(en)
|
2014-11-20 |
2016-05-26 |
Sandoz Ag |
Physical forms of ibrutinib, a bruton's kinase inhibitor
|
|
US20150224060A1
(en)
|
2015-01-03 |
2015-08-13 |
David Wong |
Gastric retentive tablet compositions
|
|
CZ201584A3
(cs)
|
2015-02-09 |
2016-08-17 |
Zentiva, K.S. |
Sůl Ibrutinib sulfátu
|
|
IL315294A
(en)
|
2015-03-03 |
2024-10-01 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
|
|
JP2018511580A
(ja)
|
2015-03-03 |
2018-04-26 |
ドクター レディズ ラボラトリーズ リミテッド |
イブルチニブの多形体
|
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
|
KR102618114B1
(ko)
|
2015-04-02 |
2023-12-27 |
라티오팜 게엠베하 |
이브루티닙과 카복실산의 공결정체
|
|
EA033992B1
(ru)
|
2015-04-06 |
2019-12-17 |
Янссен Фармацевтика Нв |
Композиции, содержащие ибрутиниб
|
|
CN105294696A
(zh)
|
2015-11-19 |
2016-02-03 |
上海创诺医药集团有限公司 |
依鲁替尼新晶型及其制备方法
|
|
CN105440040B
(zh)
|
2015-12-23 |
2018-03-13 |
浙江京新药业股份有限公司 |
依鲁替尼的纯化方法
|
|
DK3405178T3
(da)
*
|
2016-01-19 |
2025-09-22 |
Janssen Pharmaceutica Nv |
Formuleringer/sammensætninger, der omfatter en btk-inhibitor
|
|
JP7109365B2
(ja)
*
|
2016-01-19 |
2022-07-29 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｂｔｋ阻害剤を含む製剤／組成物
|
|
CN105646484A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
晶型b及制备方法
|
|
CN105646498A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
依鲁替尼晶型f及制备方法
|
|
CN105646499A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
依鲁替尼晶型g及制备方法
|
|
CN106619643A
(zh)
|
2016-11-11 |
2017-05-10 |
上海雅本化学有限公司 |
一种含依鲁替尼的药物组合物
|